Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare anemia: drug combo shows promise

NCT ID NCT04423367

Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a combination of two drugs, bortezomib and dexamethasone, in 18 adults with acquired pure red cell aplasia whose disease did not improve or came back after first treatment. The goal was to see if the combination could safely control the condition. The study is now complete.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bortezomib and dexamethasone
What this could lead to
If successful, this combination could offer a new treatment option for people with pure red cell aplasia who did not respond to or relapsed after initial therapy.
What could go wrong
This is a small, early-phase trial with only 18 participants and no comparison group, so results may not apply broadly. Side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

18 people

The number who actually took part.

Started

Sep 2020

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ECOG ≤ 2. * Age from 18 to 70. * Diagnosed with acquired pure red cell aplasia. * Meets the criteria of first-line treatment failure or relapse. * Organs in good function. * Signed informed consent. Exclusion Criteria: * Nursing woman. * Active bacterial, virus, fungal or parasitic infection, including HIV infection, HBsAg or HBV DNA positive, HCV DNA positive, etc. * Secondary PRCA caused by lymphoproliferative disorders, including large granular lymphocytic leukemia, waldenström macroglobulinemia, small lymphocytic lymphoma/chronic lymphocytic leukemia, etc. * Secondary PRCA caused by either smoldering multiple myeloma or symptomatic multiple myeloma. * Secondary PRCA caused by either ABO major mismatched stem cell transplantation or organ transplantation. * Secondary PRCA caused by solid tumors except for thymoma. * Secondary PRCA caused by drugs or pregnancy. * Secondary PRCA caused by the B19 virus. * Have contraindications for glucocorticoids, or unable to tolerate glucocorticoids for comorbidities. * Previously received treatment in other trials within 4 weeks before enrollment. * Previously treated with the proteasome inhibitor. * Experience active hemorrhage condition, including gastrointestinal bleeding, respiratory tract bleeding and central nervous system bleeding within 2 months before enrollment or during bortezomib/dexamethasone treatment. * Have a history of malignant tumors. * Have a history of mental illness. * Inability to understand or to follow study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acquired pure red cell aplasia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adult pure red cell aplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acquired pure red cell aplasia

Contacts and locations

Locations

  • Regenerative Medicine Center

    Tianjin, China

  • The Second Affilated Hospital of Shandong First Medical University

    Tai’an, Shandong, China

  • Zhoukou Central Hospital

    Zhoukou, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.